TherapeuticsMD full-year 2023 net loss $7.7M, cash $4.3M; strategic review ongoing

TherapeuticsMD, Inc.

Net loss from continuing operations $(7.7)M ($(0.74) per share) vs $1.1M income ($0.12) in 2022.
Gross license royalties $4.5M under Mayne License; net recognized $1.3M revenue and $0.5M other income.
Operating expenses fell 85.4% to $9.8M, reflecting transition from commercial pharma to royalty model.
Cash and equivalents $4.3M at Dec 31, 2023; company continues exploring strategic alternatives.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TherapeuticsMD, Inc. reported the full year ended December 31, 2023 results: net income Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, EPS $(0.74) per basic and diluted common share.

Period: the full year ended December 31, 2023
Net income: Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share
EPS: $(0.74) per basic and diluted common share
Result: reported results

Exact text from the filing

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-027998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.